AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21677121 — intervention group
Group type: COMPARATOR
Intervention: Lutein esters (Le) 27 mg (equivalent to 13.5 mg free lutein)
Number of subjects: 72
Study 18581587 — intervention group
Group type: EXPERIMENTAL
Intervention: Clotinab
Number of subjects: 124
Study 18581587 — intervention group
Group type: COMPARATOR
Intervention: ReoPro
Number of subjects: 124
Study 17307425 — intervention group
Group type: EXPERIMENTAL
Intervention: Unopposed estrogen (conjugated estrogen, 0.625 mg)
Number of subjects: 309
Study 17307425 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen + medroxyprogesterone acetate (MPA, 2.5 mg)
Number of subjects: 309
Study 17307425 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 309
Study 17307425 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined estrogen and estrogen + MPA
Number of subjects: 309
Study 17307425 — intervention group
Group type: EXPERIMENTAL
Intervention: Women who took >80% of study medication
Number of subjects: 309
Study 12943952 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 20 mg daily (flx20)
Number of subjects: 120
Study 12943952 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine 40 mg daily (flx40)
Number of subjects: 120
Study 12943952 — intervention group
Group type: COMPARATOR
Intervention: Fluoxetine 20 mg plus buspirone 20 mg daily (flx20-plus-buspirone)
Number of subjects: 120
Study 10682871 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Purine soy formula (180 mg purines/L from RNA)
Number of subjects: 178
Study 10682871 — intervention group
Group type: COMPARATOR
Intervention: Reduced Purine soy formula (65 mg purines/L; 26 mg/L from RNA and 39 mg/L from ribonucleotides)
Number of subjects: 178
Study 10682871 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard Purine soy formula
Number of subjects: 178
Study 10682871 — intervention group
Group type: COMPARATOR
Intervention: Reduced Purine soy formula
Number of subjects: 178
Study 9054254 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol plus high-dose esmolol (bolus of 1 mg/kg, then 250 micrograms.kg-1.min-1)
Number of subjects: 60
Study 9054254 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol plus low-dose esmolol (bolus of 0.5 mg/kg, then 50 micrograms.kg-1.min-1)
Number of subjects: 60
Study 9054254 — intervention group
Group type: COMPARATOR
Intervention: Propofol alone
Number of subjects: 60
Study 8356866 — intervention group
Group type: COMPARATOR
Intervention: High-flow anaesthesia using a partial rebreathing system without carbon dioxide absorption (Mapleson D)
Number of subjects: 30
Study 8356866 — intervention group
Group type: COMPARATOR
Intervention: Medium-flow anaesthesia using a circle system with carbon dioxide absorption
Number of subjects: 30
Study 8356866 — intervention group
Group type: COMPARATOR
Intervention: Low-flow anaesthesia using a circle system with carbon dioxide absorption
Number of subjects: 30
Study 2868255 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary manipulation therapy
Number of subjects: 0
Study 2868255 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 0
Study 31797330 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive remediation-enabled cognitive behaviour therapy (CR-CBT)
Number of subjects: 4
Study 30043208 — intervention group
Group type: EXPERIMENTAL
Intervention: Bevacizumab biosimilars (MIL60, BAT1706, IBI305)
Number of subjects: 0
Study 30043208 — intervention group
Group type: COMPARATOR
Intervention: Bevacizumab-EU
Number of subjects: 0
Study 27052561 — intervention group
Group type: EXPERIMENTAL
Intervention: High-resistance training (80% 1 RM, 2 × 10-15 repetitions)
Number of subjects: 56
Study 27052561 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-resistance training (20% 1 RM, 1 × 80-100 repetitions)
Number of subjects: 56
Study 27052561 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed low-resistance training (20% 1 RM followed by 40% 1 RM)
Number of subjects: 56
Study 27052561 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall resistance training (all groups combined)
Number of subjects: 56
Study 24748630 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 50 mg every 4 weeks (q4wks)
Number of subjects: 405
Study 24748630 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab 100 mg every 4 weeks (q4wks)
Number of subjects: 405
Study 24748630 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (50 mg or 100 mg) from week 24 onward
Number of subjects: 405
Study 24748630 — intervention group
Group type: EXPERIMENTAL
Intervention: Golimumab (50 mg or 100 mg)
Number of subjects: 405
Study 24748630 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (concomitant treatment)
Number of subjects: 405
Study 24748630 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 405
Study 23764521 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 2 mg/day (Phase 1) and 5 mg/day (Phase 2)
Number of subjects: 221
Study 23764521 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study 23764521 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole 2 mg/day (Phase 2)
Number of subjects: 221
Study 23764521 — intervention group
Group type: EXPERIMENTAL
Intervention: Aripiprazole
Number of subjects: 221
Study 19580465 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) 10 mg/day
Number of subjects: 30
Study 19580465 — intervention group
Group type: EXPERIMENTAL
Intervention: Alendronate (ALN) 5 mg/day
Number of subjects: 30
Study 19580465 — intervention group
Group type: COMPARATOR
Intervention: Alendronate (ALN) for 5 years plus placebo for 5 years
Number of subjects: 30
Study 19580465 — intervention group
Group type: COMPARATOR
Intervention: Healthy population
Number of subjects: 30
Study 18664276 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi (10 modified forms from classical Yang style Tai Chi), 60-minute sessions, twice weekly for 12 weeks
Number of subjects: 40
Study 18664276 — intervention group
Group type: COMPARATOR
Intervention: Attention control (wellness education and stretching), 60-minute sessions, twice weekly for 12 weeks
Number of subjects: 40
Study 16860606 — intervention group
Group type: EXPERIMENTAL
Intervention: On-pump CABG surgery (group I, n=24 patients)
Number of subjects: 42
Study 16860606 — intervention group
Group type: COMPARATOR
Intervention: Off-pump CABG (group II, n=18 patients)
Number of subjects: 42
Study 12607326 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg bid, Amoxicillin 750 mg bid, Clarithromycin 200 mg bid
Number of subjects: 3
Study 12607326 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole 30 mg bid, Amoxicillin 750 mg bid, Clarithromycin 400 mg bid
Number of subjects: 3
Study 12607326 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg, Amoxicillin 750 mg bid, Clarithromycin 400 mg bid
Number of subjects: 3
Study 12607326 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg, Amoxicillin 1,000 mg, Clarithromycin 500 mg bid
Number of subjects: 3
Study 11391837 — intervention group
Group type: EXPERIMENTAL
Intervention: zalcitabine 2.25 mg and saquinavir 1800 mg per day
Number of subjects: 24
Study 8924822 — intervention group
Group type: EXPERIMENTAL
Intervention: aprotinin inhalations thrice a day for 4-5 days
Number of subjects: 52
Study 8924822 — intervention group
Group type: COMPARATOR
Intervention: soda (placebo)
Number of subjects: 52
Study 1738222 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric feeding (17 patients)
Number of subjects: 33
Study 1738222 — intervention group
Group type: EXPERIMENTAL
Intervention: Postpylorus feeding (16 patients)
Number of subjects: 33
Study 6509283 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 6509283 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone 30 mg
Number of subjects: 60
Study 6509283 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenobarbitone 100 mg
Number of subjects: 60
Study 30188571 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 5 mg BID
Number of subjects: 5204
Study 30188571 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib 10 mg BID
Number of subjects: 5204
Study 30188571 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5204
Study 30188571 — intervention group
Group type: EXPERIMENTAL
Intervention: Tofacitinib (both dosages)
Number of subjects: 5204
Study 28722569 — intervention group
Group type: EXPERIMENTAL
Intervention: Annual mass azithromycin distributions (3 treatments during high-transmission season)
Number of subjects: 24
Study 28722569 — intervention group
Group type: EXPERIMENTAL
Intervention: Biannual mass azithromycin distributions (6 treatments: 3 during high-transmission season and 3 during low-transmission season)
Number of subjects: 24
Study 28722569 — intervention group
Group type: COMPARATOR
Intervention: Annual mass azithromycin alone
Number of subjects: 24
Study 25732409 — intervention group
Group type: EXPERIMENTAL
Intervention: Bedside polymerase chain reaction
Number of subjects: 0
Study 25732409 — intervention group
Group type: COMPARATOR
Intervention: Culture
Number of subjects: 0
Study 23905377 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural combined electroacupuncture (EA) group (Group B) with continuous EA at Zusanli (ST36) and Sanyinjiao (SP6) at a frequency of 30-100 Hz.
Number of subjects: 40
Study 23905377 — intervention group
Group type: COMPARATOR
Intervention: Epidural anesthesia group (Group A)
Number of subjects: 40
Study 21543959 — intervention group
Group type: EXPERIMENTAL
Intervention: Comprehensive psychosocial support intervention
Number of subjects: 406
Study 21543959 — intervention group
Group type: COMPARATOR
Intervention: Nursing home placement
Number of subjects: 406
Study 19332970 — intervention group
Group type: EXPERIMENTAL
Intervention: Bacillus coagulans GBI‐30, 6086
Number of subjects: 44
Study 19332970 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 44
Study 16964669 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha-2b treatment during vaccination (Group A, 12 patients)
Number of subjects: 37
Study 16964669 — intervention group
Group type: COMPARATOR
Intervention: Hepatitis B vaccine without interferon (Group B, 25 patients)
Number of subjects: 37
Study 14996138 — intervention group
Group type: EXPERIMENTAL
Intervention: Lithium
Number of subjects: 0
Study 14996138 — intervention group
Group type: EXPERIMENTAL
Intervention: Anticonvulsants
Number of subjects: 0
Study 14996138 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 11514377 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood phobic subjects during head-up tilt
Number of subjects: 11
Study 11514377 — intervention group
Group type: COMPARATOR
Intervention: Control subjects during head-up tilt
Number of subjects: 11
Study 9287255 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychological treatment conditions for IBS
Number of subjects: 84
Study 8330445 — intervention group
Group type: EXPERIMENTAL
Intervention: L‐thyroxine therapy
Number of subjects: 101
Study 8330445 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study 3090332 — intervention group
Group type: COMPARATOR
Intervention: Bolus MMC with no further treatment (Group A)
Number of subjects: 2873
Study 3090332 — intervention group
Group type: COMPARATOR
Intervention: Oral futraful for one year without MMC induction (Group C)
Number of subjects: 2873
Study 3090332 — intervention group
Group type: COMPARATOR
Intervention: Bolus MMC injection and oral futraful (Group B)
Number of subjects: 2873
Study 3090332 — intervention group
Group type: EXPERIMENTAL
Intervention: Bolus MMC and oral futraful for one year (Group B)
Number of subjects: 2873
Study 30625042 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-rich plasma (PRP) patch treatments
Number of subjects: 0
Study 30625042 — intervention group
Group type: EXPERIMENTAL
Intervention: Platelet-derived patch treatment and PRP injection
Number of subjects: 0
Study 30625042 — intervention group
Group type: COMPARATOR
Intervention: Traditional advanced wound dressings
Number of subjects: 0
Study 28298661 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade cerebral perfusion (ACP) with moderate hypothermia (24°C)
Number of subjects: 58
Study 28298661 — intervention group
Group type: COMPARATOR
Intervention: Deep hypothermic circulatory arrest (DHCA) with craniocerebral hypothermia (18°C)
Number of subjects: 58
Study 28298661 — intervention group
Group type: EXPERIMENTAL
Intervention: Antegrade cerebral perfusion (ACP)
Number of subjects: 58
Study 28298661 — intervention group
Group type: COMPARATOR
Intervention: Deep hypothermic circulatory arrest (DHCA)
Number of subjects: 58
Study 28298661 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of life (QoL)
Number of subjects: 58
Study 25060944 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine (2 mg)
Number of subjects: 26
Study 25060944 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 23570295 — intervention group
Group type: EXPERIMENTAL
Intervention: Rely X Luting Plus (3M ESPE)
Number of subjects: 30
Study 23570295 — intervention group
Group type: EXPERIMENTAL
Intervention: Maxcem Elite (Kerr Corporation)
Number of subjects: 30
Study 23570295 — intervention group
Group type: COMPARATOR
Intervention: Ketac Cem (3M ESPE)
Number of subjects: 30
Study 22192419 — intervention group
Group type: EXPERIMENTAL
Intervention: OSIT-J test in patients with PD
Number of subjects: 145
Study 22192419 — intervention group
Group type: COMPARATOR
Intervention: OSIT-J test in normal control subjects
Number of subjects: 145
Study 22192419 — intervention group
Group type: EXPERIMENTAL
Intervention: OSIT-J test in patients with MSA-P
Number of subjects: 145
Study 22192419 — intervention group
Group type: EXPERIMENTAL
Intervention: OSIT-J test in patients with PSP
Number of subjects: 145
Study 22192419 — intervention group
Group type: EXPERIMENTAL
Intervention: OSIT-J test for discriminating PD from normal control
Number of subjects: 145
Study 22192419 — intervention group
Group type: EXPERIMENTAL
Intervention: OSIT-J test for discriminating PD from MSA-P
Number of subjects: 145
Study 22192419 — intervention group
Group type: EXPERIMENTAL
Intervention: OSIT-J test for discriminating PD from PSP
Number of subjects: 145
Study 19501932 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with vitamin K2 (VK; menatetrenone; 45 mg/day) and angiotensin-converting enzyme inhibitor (ACE-I; perindopril; 4 mg/day) for 36-48 months
Number of subjects: 87
Study 19501932 — intervention group
Group type: COMPARATOR
Intervention: Vitamin K2 (VK; menatetrenone; 45 mg/day)
Number of subjects: 87
Study 19501932 — intervention group
Group type: COMPARATOR
Intervention: Angiotensin-converting enzyme inhibitor (ACE-I; perindopril; 4 mg/day)
Number of subjects: 87
Study 16492843 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous pulse oximetry (CPOX) monitoring
Number of subjects: 1219
Study 16492843 — intervention group
Group type: COMPARATOR
Intervention: Standard monitoring
Number of subjects: 1219
Study 16492843 — intervention group
Group type: EXPERIMENTAL
Intervention: CPOX monitoring
Number of subjects: 1219
Study 15270994 — intervention group
Group type: EXPERIMENTAL
Intervention: Music lessons (keyboard or voice)
Number of subjects: 144
Study 15270994 — intervention group
Group type: COMPARATOR
Intervention: Drama lessons
Number of subjects: 144
Study 15270994 — intervention group
Group type: COMPARATOR
Intervention: No lessons
Number of subjects: 144
Study 11865966 — intervention group
Group type: EXPERIMENTAL
Intervention: Roflumilast (500 microg/day)
Number of subjects: 16
Study 11865966 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 9832292 — intervention group
Group type: EXPERIMENTAL
Intervention: N-acetyl-aspartyl-glutamic acid (NAAGA)
Number of subjects: 10
Study 9832292 — intervention group
Group type: COMPARATOR
Intervention: Placebo (lactose)
Number of subjects: 10
Study 8587272 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (PVS)
Number of subjects: 0
Study 8587272 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 2475682 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained-release verapamil (240 mg once daily)
Number of subjects: 26
Study 2475682 — intervention group
Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 26
Study 979075 — intervention group
Group type: EXPERIMENTAL
Intervention: Proximal selective vagotomy with pyloroplasty
Number of subjects: 0
Study 979075 — intervention group
Group type: COMPARATOR
Intervention: Proximal selective vagotomy without pyloroplasty
Number of subjects: 0
Study 30753203 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclic inflation and deflation of pneumatic cuffs wrapped around the subject's thighs
Number of subjects: 22
Study 30753203 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 22
Study 28301686 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-operative treatment with daily site-specific oral hygiene using fluoridated toothpaste, professional topical fluoride treatment, and dietary advice.
Number of subjects: 39
Study 28301686 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-operative treatment
Number of subjects: 39
Study 26371618 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based cognitive therapy (MBCT)
Number of subjects: 92
Study 26371618 — intervention group
Group type: COMPARATOR
Intervention: Active control condition (ACC)
Number of subjects: 92
Study 23400564 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg plus gp100 vaccine
Number of subjects: 676
Study 23400564 — intervention group
Group type: EXPERIMENTAL
Intervention: Ipilimumab 3 mg/kg plus placebo
Number of subjects: 676
Study 23400564 — intervention group
Group type: COMPARATOR
Intervention: gp100 vaccine plus placebo
Number of subjects: 676
Study 21557816 — intervention group
Group type: EXPERIMENTAL
Intervention: Fresh frozen plasma
Number of subjects: 19
Study 21557816 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate
Number of subjects: 19
Study 19725594 — intervention group
Group type: EXPERIMENTAL
Intervention: CNTO 528 at 0.03 mg/kg
Number of subjects: 24
Study 19725594 — intervention group
Group type: EXPERIMENTAL
Intervention: CNTO 528 at 0.09 mg/kg
Number of subjects: 24
Study 19725594 — intervention group
Group type: EXPERIMENTAL
Intervention: CNTO 528 at 0.3 mg/kg
Number of subjects: 24
Study 19725594 — intervention group
Group type: EXPERIMENTAL
Intervention: CNTO 528 at 0.9 mg/kg
Number of subjects: 24
Study 19725594 — intervention group
Group type: COMPARATOR
Intervention: CNTO 528
Number of subjects: 24
Study 17724294 — intervention group
Group type: EXPERIMENTAL
Intervention: Statin withdrawal for the first 3 days after admission (n = 46)
Number of subjects: 215
Study 17724294 — intervention group
Group type: COMPARATOR
Intervention: Atorvastatin 20 mg/day (n = 43)
Number of subjects: 215
Study 17724294 — intervention group
Group type: COMPARATOR
Intervention: Statin withdrawal compared to non-randomized patients without previous statin therapy (n = 126)
Number of subjects: 215
Study 15134708 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection into the right trapezius muscle
Number of subjects: 14
Study 15134708 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic saline injection into the right trapezius muscle
Number of subjects: 14
Study 15134708 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertonic saline injection into the right temporalis muscle
Number of subjects: 14
Study 15134708 — intervention group
Group type: EXPERIMENTAL
Intervention: Isotonic saline injection into the right temporalis muscle
Number of subjects: 14
Study 11475708 — intervention group
Group type: EXPERIMENTAL
Intervention: Philips Jordan HP735 electric toothbrush
Number of subjects: 49
Study 11475708 — intervention group
Group type: COMPARATOR
Intervention: Manual toothbrush
Number of subjects: 49
Study 9728842 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg of intrathecal ropivacaine plus sufentanil 10 microg (R2)
Number of subjects: 48
Study 9728842 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg of intrathecal ropivacaine plus sufentanil 10 microg (R4)
Number of subjects: 48
Study 9728842 — intervention group
Group type: COMPARATOR
Intervention: 2.5 mg of intrathecal bupivacaine plus sufentanil 10 microg (B)
Number of subjects: 48
Study 8293822 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcervical intrafallopian transfer of zygotes
Number of subjects: 145
Study 8293822 — intervention group
Group type: COMPARATOR
Intervention: Intrauterine transfer of cleaved embryos
Number of subjects: 145
Study 29368880 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise group (N=20)
Number of subjects: 80
Study 29368880 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression and exercise group (N=20)
Number of subjects: 80
Study 29368880 — intervention group
Group type: COMPARATOR
Intervention: Control group (N=20)
Number of subjects: 80
Study 29368880 — intervention group
Group type: COMPARATOR
Intervention: Compression therapy group (N=20)
Number of subjects: 80
Study 26578306 — intervention group
Group type: EXPERIMENTAL
Intervention: Anterior referencing (AR) technique
Number of subjects: 20
Study 26578306 — intervention group
Group type: COMPARATOR
Intervention: Posterior referencing (PR) technique
Number of subjects: 20
Study 24445098 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous Quality Improvement (CQI) approach
Number of subjects: 40
Study 24445098 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-Directed (SD) practices
Number of subjects: 40
Study 24445098 — intervention group
Group type: EXPERIMENTAL
Intervention: Reflective Adaptive Process (RAP) approach
Number of subjects: 40
Study 24445098 — intervention group
Group type: COMPARATOR
Intervention: Control group (Self-Directed practices)
Number of subjects: 40
Study 23334115 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.5% (10 mL)
Number of subjects: 60
Study 23334115 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine 0.75% (10 mL)
Number of subjects: 60
Study 23334115 — intervention group
Group type: COMPARATOR
Intervention: Control group (no wound infiltration)
Number of subjects: 60
Study 20464949 — intervention group
Group type: EXPERIMENTAL
Intervention: No tourniquet used (Group I)
Number of subjects: 84
Study 20464949 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet used, deflated for hemostasis after component insertion (Group II)
Number of subjects: 84
Study 20464949 — intervention group
Group type: EXPERIMENTAL
Intervention: Tourniquet used, deflated after wound closure (Group III)
Number of subjects: 84
Study 18471341 — intervention group
Group type: EXPERIMENTAL
Intervention: lornoxicam (16 mg, i.v.)
Number of subjects: 20